# Palliative Osimertinib Rechallenge Achieving Rapid Improvement in Leptomeningeal Carcinomatosis After Prior Osimertinib‐Induced ILD

## TL;DR

A patient with lung cancer showed rapid improvement after being treated again with osimertinib, despite a prior allergic reaction.

## Contribution

Demonstrates successful osimertinib rechallenge for leptomeningeal carcinomatosis after prior drug-induced lung injury.

## Key findings

- Osimertinib rechallenge led to neurological improvement and radiological response.
- No recurrence of osimertinib-induced ILD was observed during rechallenge.
- The case suggests potential for reusing EGFR inhibitors in exceptional clinical scenarios.

## Abstract

A patient with EGFR‐mutant lung cancer developed leptomeningeal carcinomatosis years after osimertinib‐induced ILD. With no other treatment options, palliative osimertinib rechallenge led to rapid neurological improvement and radiological response, without ILD recurrence. This case highlights the potential of carefully monitored osimertinib rechallenge for symptomatic relief in exceptional cases.

This case highlights the potential of carefully monitored osimertinib rechallenge for symptomatic relief in exceptional cases.